Insight

Jul 19, 2024, 13:45

Homologous recombination deficient breast cancer are more sensitive to chemo-radiotherapy

Memorial Sloan Kettering Radiation Oncology shared on X about a recent paper titled “Increased synthetic cytotoxicity of combinatorial chemo-radiotherapy in homologous recombination deficient tumors” in International Journal of Radiation Oncology, Biology, Physics.

Authors. Jennifer Ma, Rachna Shah, Andrew C. Bell, Jorge S. Reis-Filho, Nadeem Riaz, Simon N. Powell et al.

Homologous recombination

“New in International Journal of Radiation Oncology, Biology and Physics – The Red Journal from Dr Jennifer Ma et al: Homologous recombination deficient breast cancer (HRD via BRCA 1/2, functional test or mutational signature) are more sensitive to chemoRT vs isogenic controls or tumors without HRD mutational signature.”

Source: Memorial Sloan Kettering Radiation Oncology/X

Andrew C. Bell BRCA Breast Cancer cancer chemoRT IJROBP IJROBP - The Red Journal International Journal of Radiation Oncology Biology Physics Jennifer Ma Jorge S. Reis-Filho Memorial Sloan Kettering Radiation Oncology Nadeem Riaz OncoDaily Oncology Rachna Shah Simon N. Powell

Esophageal Cancer: Symptoms, Causes, Stages, Diagnosis & Treatment

Faster, Flexible and Affordable: Mikhail Groubman on Building a Global Legacy in Clinical Research in an Untapped Market

Invest in Health Policy: A Conversation with Professor Andreas Charalambous

FDA Approves Cosibelimab-ipdl for Treatment of Metastatic or Locally Advanced Cutaneous Squamous Cell Carcinoma

Dolph Lundgren’s Fight for Life: How He Survived Kidney Cancer After 9 Years of Battle

Special Coverage